Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Stem Cell Research & TherapeuticsOpen Access

From missed mutations to liquid clues: a new era of EGFR diagnostics in NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

TBTawil BillDNDrew Norma

Discussion

Loading...

Member takes

Overview

Review highlights EGFR-targeted therapies and liquid biopsy's role in enhancing mutation detection and precision oncology.

Key Points

  • Liquid biopsy improves mutation detection in non-small cell lung cancer, enhancing clinical decision-making.
  • Current techniques like PCR, NGS, and ddPCR are assessed for efficacy, revealing limitations in traditional methods.
  • The review explores CRISPR-based diagnostics and nanotechnology's potential to revolutionize EGFR detection.
  • Integrating high-sensitivity approaches may optimize patient outcomes in EGFR-driven malignancies.

Cite This Study

Bill et al. (2025) studied this question.

synapsesocial.com/papers/68c23bd7b210217d647864dfhttps://doi.org/10.15406/jsrt.2025.10.00193
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management2025 · 21 citations
  2. 2EGFR-Directed Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer2025
  3. 3Lung Cancer in the Era of Precision Oncology2025
  4. 4[Expert consensus on the diagnosis and treatment of advanced non-small cell lung cancer with EGFR PACC mutations (2025 edition)].2025
  5. 5Overcoming Resistance in EGFR‐Mutant Cancers: A Comprehensive Review of Inhibitor Evolution and SAR‐Based Design2026 · 10 citations